Today, Corbus Pharmaceuticals announced that the European Commission has approved orphan designation for lenabasum in the treatment of dermatomyositis...
Corbus Pharmaceuticals announced today that they will proceed with a Phase 3 clinical trial to evaluate the efficacy and...
Get Support!
Recently posted
-
Managing Your Expectations with Movement & Exercise with Kourage Health March 3, 2025
-
Meet Elisa Glass: MSU’s First Executive Director – Vision & Journey February 17, 2025
-
Catch the Replay: “Your Health, Your Voice: Building a Lifesaving Medical Binder” with the Three Myositis Musketeers! January 23, 2025
